Loss of TRAIL-Receptors Is a Recurrent Feature in Pancreatic Cancer and Determines the Prognosis of Patients with No Nodal Metastasis after Surgery

Gallmeier, Eike; Bader, Dominik C.; Kriegl, Lydia; Berezowska, Sabina; Seeliger, Hendrik; Göke, Burkhard; Kirchner, Thomas; Bruns, Christiane; De Toni, Enrico N.
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Introduction: Agonistic antibodies targeting TRAIL-receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are being developed as a novel therapeutic approach in cancer therapy including pancreatic cancer. However, the cellular distribution of these receptors in primary pancreatic cancer samples has not been sufficiently investigated and no study has yet addressed the issue of their prognostic significance in this tumor entity. Aims and Methods: Applying tissue microarray (TMA) analysis, we performed an immunohistochemical assessment of TRAIL-receptors in surgical samples from 84 consecutive patients affected by pancreatic adenocarcinoma and in 26 additional selected specimens from patients with no lymph nodes metastasis at the time of surgery. The prognostic significance of membrane staining and staining intensity for TRAIL-receptors was evaluated. Results: The fraction of pancreatic cancer samples with positive membrane staining for TRAIL-R1 and TRAIL-R2 was lower than that of cells from surrounding non-tumor tissues (TRAIL-R1: p<0.001, TRAIL-R2: p = 0.006). In addition, subgroup analyses showed that loss of membrane staining for TRAIL-R2 was associated with poorer prognosis in patients without nodal metastases (multivariate Cox regression analysis, Hazard Ratio: 0.44 [95% confidence interval: 0.22−0.87]; p = 0.019). In contrast, analysis of decoy receptors TRAIL-R3 and -R4 in tumor samples showed an exclusively cytoplasmatic staining pattern and no prognostic relevance. Conclusion: This is a first report on the prognostic significance of TRAIL-receptors expression in pancreatic cancer showing that TRAIL-R2 might represent a prognostic marker for patients with early stage disease. In addition, our data suggest that loss of membrane-bound TRAIL-receptors could represent a molecular mechanism for therapeutic failure upon administration of TRAIL-receptors-targeting antibodies in pancreatic cancer. This hypothesis should be evaluated in future clinical trials.


Related Articles

  • Systemic treatment approaches in HER.2-negative advanced breast cancer—guidance on the guidelines. Joy, A. A.; Ghosh, M.; Fernandes, R.; Clemons, M. J. // Current Oncology;Mar2015 Supplement 1, Vol. 22, pS29 

    Despite advancements in the treatment of early-stage breast cancer, many patients still develop disease recurrence; others present with de novo metastatic disease. For most patients with advanced breast cancer, the primary treatment intent is noncurative—that is, palliative—in...

  • Prostate cancer survivorship: a new path for uro-oncology. Goonewardene, S.; Nanton, V.; Young, A.; Persad, R.; Makar, A. // World Journal of Urology;Jan2015, Vol. 33 Issue 1, p151 

    No abstract available.

  • Fluorescence-Guided Surgery in Combination with UVC Irradiation Cures Metastatic Human Pancreatic Cancer in Orthotopic Mouse Models. Hiroshima, Yukihiko; Maawy, Ali; Zhang, Yong; Sato, Sho; Murakami, Takashi; Yamamoto, Mako; Uehara, Fuminari; Miwa, Shinji; Yano, Shuya; Momiyama, Masashi; Chishima, Takashi; Tanaka, Kuniya; Bouvet, Michael; Endo, Itaru; Hoffman, Robert M. // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    The aim of this study is to determine if ultraviolet light (UVC) irradiation in combination with fluorescence-guided surgery (FGS) can eradicate metastatic human pancreatic cancer in orthotopic nude–mouse models. Two weeks after orthotopic implantation of human MiaPaCa-2 pancreatic cancer...

  • Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. Yamaue, Hiroki; Satoi, Sohei; Kanbe, Takamasa; Miyazawa, Motoki; Tani, Masaji; Kawai, Manabu; Hirono, Seiko; Okada, Kenichi; Yanagimoto, Hiroaki; Kwon, A-Hon; Mukouyama, Tomoyuki; Tsunoda, Hiroaki; Chijiiwa, Kazuo; Ohuchida, Jiro; Kato, Jun; Ueda, Kazuki; Yamaguchi, Taketo; Egawa, Shinichi; Hayashi, Kazuhiko; Shirasaka, Tetsuhiko // Cancer Chemotherapy & Pharmacology;Jan2014, Vol. 73 Issue 1, p97 

    Purpose: Based on the results of first-line chemotherapy for advanced pancreatic cancer, S-1 was confirmed to be non-inferior to gemcitabine. However, the recommended regimen of 4 weeks of administration followed by 2 weeks of drug withdrawal frequently causes adverse effects. On the other hand,...

  • Pancreatic cancer in the remnant pancreas following primary pancreatic resection. Hashimoto, Daisuke; Chikamoto, Akira; Ohmuraya, Masaki; Sakata, Kazuya; Miyake, Keisuke; Kuroki, Hideyuki; Watanabe, Masayuki; Beppu, Toru; Hirota, Masahiko; Baba, Hideo // Surgery Today;Jul2014, Vol. 44 Issue 7, p1313 

    Purpose: To clarify the clinical features of cancer in the pancreatic remnant. Methods: We retrospectively reviewed the clinical and pathological findings of 10 patients who developed remnant pancreatic cancer in our hospital between 2002 and 2012. The KRAS sequences in both the initial...

  • Polyphenols from marine brown algae target radiotherapy-coordinated EMT and stemness-maintenance in residual pancreatic cancer. Aravindan, Sheeja; Ramraj, Satish Kumar; Somasundaram, Somasundaram T.; Herman, Terence S.; Aravindan, Natarajan // Stem Cell Research & Therapy;9/23/2015, Vol. 6 Issue 1, p1 

    Introduction: Therapy-associated onset of stemness-maintenance in surviving tumor-cells dictates tumor relapse/recurrence. Recently, we recognized the anti-pancreatic cancer (PC) potential of seaweed polyphenol manifolds and narrowed down three superior drug-deliverables that could serve as...

  • P2–028A CASE OF UNDIFFERENTIATED CARCINOMA OF THE PANCREAS SHOWING RESPONSE TO TC AFTER FAILURE OF GEM AND S-1. Okazaki, S.; Yamamoto, T.; Ikai, I.; Yasui, H. // Annals of Oncology;Nov2013 Supplement 9, Vol. 24, pix79 

    No abstract available.

  • Colon and Anorectum - Cancer Including Diagnosis, Prevention and Screen.  // Gut;2015 Supplement1, Vol. 64, pA178 

    The article presents abstracts on colon and anorectum in cancer topics including effect of participation in bowel cancer screening programme (BCSP) on emergency admission in bowel cancer patients, resection of colorectal liver metastases (CRLM) and synchronous colorectal liver metastases (sCRLM).

  • ANATOMICAL FEATURES OF CT SCAN EXPLORATION IN PANCREATIC TUMORS. Frâncu, L. L.; Tanase, Genoveva Ionela; Petrusca, Mirona // Romanian Journal of Functional & Clinical, Macro- & Microscopica;2015, Vol. 14 Issue 3, p416 

    Screening for pancreatic cancer and its precursor lesions in the general population is not feasible, but high-risk subpopulations seem to be suitable targets for screening programs. We have done CT scan investigations of the pancreatic tumors under observation to emphasize and confirm the damage...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics